← Eichor
Condition: Selinexor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Selinexor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/Phase 2 · 5 location(s) · Tong Chen, MD · NCT05698147"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Phase 1/Phase 2 · 1 location(s) · Mingzhi Zhang · NCT06559553A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06556199Golidocitinib Combined With Selinexor for CAEBVD
Phase 2/Phase 3 · 1 location(s) · Beijing Friendship Hospital · NCT07369739Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Particip
Phase 3 · 166 location(s) · AbbVie · NCT06158841A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ
NA · 1 location(s) · Ruijin Hospital · NCT07191431Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Samsung Medical Center · NCT06552559Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06517511Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Phase N/A · 1 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06933277A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Phase 2 · 70 location(s) · Karyopharm Therapeutics Inc · NCT05980806HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Phase 2 · 1 location(s) · Duke University · NCT06822972A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · 127 location(s) · National Cancer Institute (NCI) · NCT05099003Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/Phase 2 · 25 location(s) · Karyopharm Therapeutics Inc · NCT02343042Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple
Phase 1/Phase 2 · 1 location(s) · Natalie Callander · NCT07479979NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2 · 1 location(s) · Loyola University · NCT05983276Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif
Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT07523737Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Phase 2 · 4 location(s) · Shanghai Tong Ren Hospital · NCT05736978A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3 · 1 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT07011056A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06966154Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074470Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
Phase N/A · 1 location(s) · Shanxi Bethune Hospital · NCT07514052Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Phase 2 · 3 location(s) · University of Miami · NCT05530421A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1 · 1 location(s) · Oncotherapeutics · NCT06225310Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05333458Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Phase 1/Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT05035745A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Phase 2 · 16 location(s) · Memorial Sloan Kettering Cancer Center · NCT05985161
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.